-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Amari ...

Bangkok, Thailand, June 07, 2024 (GLOBE NEWSWIRE) -- LA BOUTIQUE This new location promises to be a premier destination for high-end fashion enthusiasts and tourists visiting Bangkok, Thailand. Celebrating 12 years in the fashion industry, LA BOUTIQUE has consistently pushed the boundaries of design and innovation, creating timeless pieces that captivate audiences worldwide. The brand’s exquisite collections have been worn by international celebrities such as Eva Longoria, Olivia Palermo, and Kristina Baza ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin's exclusive distributor in the country -- DUBLIN, Irela ...

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin’s exclusive distributor in the country -- DUBLIN, Irela ...

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast:https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624   The session ...

Amarin Corporation Plc (AMRN) reported first-quarter 2024 adjusted loss of 2 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 5 cents per share. The company had recorded an adjusted loss of 4 cents in the year-ago quarter.Total revenues were $56.5 million, which beat the Zacks Consensus Estimate of $51.0 million. However, revenues declined 34% from the year-ago quarter’s levels, owing to lower product revenues.Despite the better-than-expected results, shares of Amarin were ...

Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Patrick Holt – President and Chief Executive Officer Jonathan Provoost – Chief Legal and Compliance Officer Steve Ketchum – President-R&D and Chief Scientific Officer Tom Reilly – Chief Financial Officer Conference Call Participants Roanna Ruiz – Leerink Partners Paul Choi – Goldman Sachs Operator Good day, and welcome ...

Exhibit 99.1 Amarin Reports First Quarter 2024 Business Update and Financial Results -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 '24 versus Q4 '23 Driven by Spain and the UK -- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Foll ...